Home › Stelis Biopharma And Pieris Forge Alliance For Novel Anticalin Therapeutics In Ophthalmology
 

Keywords :   


Stelis Biopharma And Pieris Forge Alliance For Novel Anticalin Therapeutics In Ophthalmology

2013-12-30 06:46:05| drugdiscoveryonline News Articles

Stelis Biopharma (formerly Agila Biotech), a subsidiary of Strides Arcolab Limited, focused on biotherapeutic drug development and bio-manufacturing, and Pieris AG, a next generation therapeutic protein R&D company, recently announced the initiation of a long-term collaboration for clinical development and commercialization of multiple novel Anticalin-based protein therapeutics worldwide, primarily focusing on ophthalmology

Tags: in alliance forge ophthalmology

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.10Mark Andy appoints Antony Cotton European sales manager
07.10Hurricane Milton Potential Storm Surge Flooding Map
07.10Evonik, BASF Agree on First Delivery of Biomass-Balanced Ammonia
07.10Hurricane Milton Update Statement
07.10Summary for Hurricane Milton (AT4/AL142024)
07.10Hurricane Milton Probabilistic Storm Surge Graphics
07.10MCC acquires smart label solutions provider Starport Technologies
07.10UPM Raflatac announces Packaging Recyclability Guide
More »